Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease

Kidney International
C ZoccaliLorenzo Malatino

Abstract

Urotensin II (UTN) is a vasoactive substance that may induce vasoconstriction or vasodilatation. Although this peptide is seen as a vasculotoxic substance, to date there is no prospective study examining the relationship between UTN and hard end points like cardiovascular (CV) events. UTN is much increased in end-stage renal disease (ESRD) and this disease may represent a useful natural model to explore the relationship between UTN and CV outcomes. In this study, we analysed the relationship between plasma UTN and incident CV events (fatal and non-fatal) in a cohort of 191 haemodialysis patients followed up for an average time of 3.6 years (range 0.07-5.8 years). Plasma UTN in haemodialysis patients (median: 6.5 ng/ml) was twice higher than in healthy subjects (median: 3.3 ng/ml). During the follow-up period, 94 patients died and 88 had incident fatal and non-fatal CV events. UTN was significantly lower in patients with incident CV events (median: 5.3 ng/ml) than in events-free patients (median: 7.1 ng/ml), and in a Kaplan-Meier analysis, high UTN was strongly and inversely associated with incident CV events (P<0.001). Multivariate Cox's regression analysis fully confirmed plasma UTN as an inverse predictor of adverse CV outcom...Continue Reading

References

Dec 3, 1999·Biochemical and Biophysical Research Communications·Q LiuC T Caskey
Aug 22, 2000·British Journal of Pharmacology·F E BottrillR White
Feb 13, 2001·American Journal of Physiology. Heart and Circulatory Physiology·A StirratM R MacLean
Apr 20, 2001·British Journal of Pharmacology·S M GardinerT Bennett
Jun 26, 2001·Journal of the American Society of Nephrology : JASN·Carmine ZoccaliLorenzo Salvatore Malatino
Sep 21, 2001·Lancet·J Affolter, D J Webb
Sep 21, 2001·Lancet·K TotsuneO Murakami
Jan 12, 2002·British Journal of Pharmacology·Felix Böhm, John Pernow
Jun 22, 2002·Lancet·Stephen A DouglasAdel Giaid
Sep 21, 2002·Lancet·A Mark RichardsTimothy G Yandle
Oct 17, 2002·British Journal of Pharmacology·Janet J Maguire, Anthony P Davenport
Nov 26, 2002·Journal of Hepatology·Jörg HellerTilman Sauerbruch
Dec 4, 2002·Circulation·Leong L NgJoan E Davies
Dec 7, 2002·Regulatory Peptides·Thomas DschietzigKarl Stangl
Jan 10, 2003·Clinical Science·Kazuhito TotsuneOsamu Murakami
Feb 5, 2003·Blood Purification·Carmine ZoccaliGiovanni Tripepi
Mar 13, 2003·Kidney International·Kamyar Kalantar-ZadehJoel D Kopple
Jun 7, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Fraser D RussellPeter Molenaar
Oct 29, 2003·Circulation·Mark J SarnakUNKNOWN American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology,
Jan 30, 2004·JAMA : the Journal of the American Medical Association·Yongmei LiuMichael J Klag
Mar 5, 2004·International Journal of Cardiology·Harald LappJohannes-Peter Stasch
Mar 31, 2004·Canadian Journal of Physiology and Pharmacology·Gabrielle GendronDomenico Regoli
Jun 18, 2004·Journal of Hypertension·Bernard M Y CheungLouisa Y F Wong
Sep 2, 2004·British Journal of Pharmacology·Sheila M GardinerTerence Bennett
Oct 13, 2004·Peptides·A Mark Richards, Chris Charles
Jun 1, 2005·European Journal of Heart Failure·Stefan KrügerUwe Janssens

❮ Previous
Next ❯

Citations

Aug 8, 2007·Journal of Anesthesia·John McDonaldDavid G Lambert
Dec 5, 2006·Current Hypertension Reports·Nicolas Bousette, Adel Giaid
Jul 14, 2010·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Ari MosenkisRaymond R Townsend
Feb 16, 2008·Current Opinion in Nephrology and Hypertension·Carmine ZoccaliFrancesca Mallamaci
Dec 1, 2012·Current Opinion in Nephrology and Hypertension·Robyn G Langham, Darren J Kelly
Aug 31, 2006·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Takuya WatanabeTakashi Katagiri
Apr 29, 2009·The Tohoku Journal of Experimental Medicine·Orhan OzerBehcet Al
Jun 30, 2006·Kidney International·N Ashton
Jul 9, 2008·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Rajbabu Pakala
Oct 16, 2007·Peptides·Markus Tölle, Markus van der Giet
Jul 6, 2007·Peptides·Kwok Leung OngBernard M Y Cheung
May 2, 2006·American Journal of Hypertension·Francesca MallamaciCarmine Zoccali
Oct 1, 2008·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Pitchai BalakumarManjeet Singh
Dec 19, 2007·Hypertension·Carmine ZoccaliLorenzo Malatino
Oct 3, 2009·Clinical Chemistry·Yen-Hsing ChenSuetonia C Palmer
Apr 28, 2010·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Bryan RossAdel Giaid

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.